Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

We performed a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose-response study of the efficacy and safety of the oral administration of PG-116800, a matrix metalloproteinase (MMP) inhibitor, in patients with mild to moderate knee osteoarthritis. The primary efficacy en...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzeski, Piotr, Buckland-Wright, Chris, Bálint, Géza, Cline, Gary A, Stoner, Karen, Lyon, Robert, Beary, John, Aronstein, William S, Spector, Tim D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212568/
https://www.ncbi.nlm.nih.gov/pubmed/17958901
http://dx.doi.org/10.1186/ar2315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212568/
https://www.ncbi.nlm.nih.gov/pubmed/17958901
http://dx.doi.org/10.1186/ar2315

Ejemplares similares